Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a key upgrade at its Boonton, New Jersey, site. The state-of-the-art formulation, fill and finish services facility has received a controlled substances registration. As a result, the team can now handle, store, manufacture and test Schedule II and III controlled substances.
The registration builds on the facility’s existing high-potency handling capabilities. Moreover, it strengthens Aptar Pharma Services’ specialized support for complex pharmaceutical products. In addition, it gives drug developers a more complete option in a regulated setting.
Customers now have broader access to integrated services. These customers develop controlled substance therapies, including central nervous system (CNS), pain management and other specialty pharmaceutical products. They can use integrated chemistry, manufacturing and controls (CMC) and early clinical supply services. Importantly, all of this happens within a controlled and compliant environment.
Valerie Otte, Director of Business Development, Aptar Pharma Services, said, “Our goal is to make it easier for customers to advance complex and innovative drug products into clinical development. Adding Schedule II-III controlled substance capabilities is another step in building a comprehensive development and manufacturing platform for inhaled and nasal drug products.”
One Partner for Inhaled and Nasal Drug Development
The Boonton site is part of Aptar Pharma Services. This FDA-inspected facility manufactures clinical trial materials. Therefore, customers can work with a single partner across the full development path.
The services cover formulation development, technology transfer and GMP clinical trial materials manufacturing. They also include analytical testing, stability studies and fill-finish services. Furthermore, the team provides regulatory support for orally inhaled and nasal drug products (OINDPs).
Aptar Pharma also pairs these services with its drug delivery device technologies. Consequently, the Boonton site can help customers streamline development, manufacturing and regulatory support. Customers no longer need to coordinate multiple external vendors. As a result, they can accelerate their progress to the clinic.
Dr. Paul Shields, Site Director at Aptar Pharma’s Boonton site, added, “This facility has previously handled controlled substances across several dosage forms, so the controls and experience are already well-embedded in our operations. This puts us in a strong position to support a broader range of customer programs while maintaining the highest standards of quality, compliance and security.”
Overall, the new registration marks a clear step forward for Aptar Pharma Services. Similarly, it signals the company’s focus on complex therapies that need careful handling. Finally, developers of inhaled and nasal drug products now gain a capable partner under one roof.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com